853643-60-4

Basic information

• Product Name: tert-butyl 4-(3-bromophenyl)-3,6-dihydropyridine-1(2H)-carboxylate
• Synonyms: tert-butyl 4-(3-bromophenyl)-3,6-dihydropyridine-1(2H)-carboxylate
• CAS NO: 853643-60-4
• Molecular Weight: 338.244
• Mol File: 853643-60-4.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: tert-butyl 4-(3-bromophenyl)-3,6-dihydropyridine-1(2H)-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-(3-bromophenyl)-3,6-dihydropyridine-1(2H)-carboxylate(853643-60-4)
• EPA Substance Registry System: tert-butyl 4-(3-bromophenyl)-3,6-dihydropyridine-1(2H)-carboxylate(853643-60-4)

Safety Data

• Hazardous Substances Data: 853643-60-4(Hazardous Substances Data)

Upstream product

• 591-18-4 1-Bromo-3-iodobenzene 
• 375853-82-0 tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-1(2H)-pyridinecarboxylate 

Downstream Products

• 1394066-66-0 tert-butyl 4-{3-[3-(pyrazin-2-ylamino)-1H-indazol-1-yl]phenyl}-3,6-dihydropyridine-1(2H)-carboxylate 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS

The present invention provides a heterocyclic compound a TLR7 and/or TLR9 and/or TLR-7/8/9 and/or TLR-7/8 and/or TLR-7/9 inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases and/or inflammatory diseases and the like, in particular, acute decompensated heart failure, non-alcoholic steatohepatitis (NASH), IgA nephropathy, Duchenne muscular dystrophy (DMD), systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, psoriasis, inflammatory bowel disease, asthma, type 1 diabetes, myasthenia gravis, hematopoetic disfunction, B-cell malignancies, transplant rejection and graft-versus-host disease, hepatocellular carcinoma (HCC) and the like. The present invention is a compound represented by the formula (1) : wherein each symbol is as described in the specification, or a salt thereof.

Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors

The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by inhibition of Syk kinase and/or Janus kinases.

4-PHENYLPIPERIDINE DERIVATIVES AS RENIN INHIBITORS

Compounds of the present invention having the formula (I) exhibit inhibitory activity on the natural enzyme renin. Thus, compounds of formula (I) may be employed for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.